Venous Ulcers – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Venous Ulcers Market Outlook
Thelansis’s “Venous Ulcers Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Venous Ulcers treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Venous Ulcers Overview
Venous
ulcers are skin lesions that occur in areas affected by venous hypertension.
Risk factors for venous ulcers include age 55 years or older, family history of
chronic venous insufficiency, higher body mass index, history of pulmonary
embolism or superficial/deep venous thrombosis, lower extremity skeletal or
joint disease, higher number of pregnancies, parental history of ankle ulcers,
physical inactivity, history of ulcers, severe lipodermatosclerosis
(panniculitis that leads to skin induration or hardening, increased
pigmentation, swelling, and redness), and venous reflux in deep veins. Poor
prognostic signs for healing include ulcer duration longer than three months,
ulcer length of 10 cm (3.9 in) or more, presence of lower limb arterial
disease, advanced age, and elevated body mass index. Complications of venous
ulcers include infections and skin cancers such as squamous cell carcinoma.
Although venous ulcers are the most common type of chronic lower extremity
ulcers, the differential diagnosis should consist of arterial occlusive disease
(or a combination of arterial and venous disease), ulceration caused by
diabetic neuropathy, malignancy, pyoderma gangrenosum, and other inflammatory
ulcers.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment